Leukine is named as an intervention in 7 current clinical trials in our Australia, Israel, Norway, Canada, Mexico, Spain, Sweden and Denmark registers. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Children's Oncology Group (2). The most-studied condition is Stage III Cutaneous Melanoma AJCC v7.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Stage III Cutaneous Melanoma AJCC v7 | 2 |
| Cancer | 1 |
| Cancer, Lung | 1 |
| Cancer of Lung | 1 |
| Mesothelioma | 1 |
| Oncology | 1 |
| NSCLC Stage IV | 1 |
| NSCLC, Stage III | 1 |
| Ganglioneuroblastoma, Nodular | 1 |
| Neuroblastoma | 1 |
| High Risk Neuroblastoma | 1 |
| Recurrent Neuroblastoma | 1 |
| Refractory Neuroblastoma | 1 |
| Stage IV Cutaneous Melanoma AJCC v6 and v7 | 1 |
| Advanced Melanoma | 1 |
| Metastatic Melanoma | 1 |
| Recurrent Melanoma | 1 |
| Glioblastoma | 1 |
| Gliosarcoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Children's Oncology Group | 2 |
| National Cancer Institute (NCI) | 2 |
| Åslaug Helland | 1 |
| Vestre Viken Hospital Trust | 1 |
| Roswell Park Cancer Institute | 1 |
A trial with sites in more than one country appears in each of those registers.
7 current trials in our Australia, Israel, Norway, Canada, Mexico, Spain, Sweden and Denmark registers name Leukine as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 7 trials is recruiting: 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Children's Oncology Group (2), National Cancer Institute (NCI) (2), Åslaug Helland (1) and Vestre Viken Hospital Trust (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Leukine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Leukine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Leukine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.